|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer |
| Rana McKay, MD |
| Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations. This study, inspired by the success of PARP inhibitors in metastatic settings and neoadjuvant successes in other cancers, aims to address the aggressive nature of BRCA-mutated prostate cancer earlier in the disease course. |
|
|
|
|
|
|
|
|
|
|
|
| Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer |
Emmanuel Antonarakis, MD, and Jacob Orme, MD, Ph.D.
Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study's genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. |
|
|
|
|
|
|
|
|
|
|
| PARP Inhibitors: Targeting DNA Repair Pathways |
| Neal Shore, MD, FACS |
| Neal Shore joins Fred Saad as part of an independent medical initiative discussing PARP Inhibitors and the mechanism of action of why PARP inhibitors matter now as monotherapy, as well as in combination. |
|
|
|
|
|
|
|
|
|
|
|
| NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
|
| Rana McKay, MD
|
| NePtune is a phase 2 study investigating neoadjuvant PARP inhibition followed by radical prostatectomy in patients with unfavorable intermediate-risk or high-risk prostate cancer and BRCA1/2 gene alterations, a population with a heightened risk of relapse and aggressive disease. The trial aims to assess the efficacy of olaparib combined with an LHRH agonist for 6 months followed by surgery, with primary endpoints including the rate of pathologic complete response or minimum residual disease.
|
|
|
|
|
|
| PARP Inhibitor Therapy for Prostate Cancer Patients: Emerging Combinations
|
| Zachary Klaassen, MD, MSc, and Rashid Sayyid, MD, MSc
|
| PARP inhibitors show promise in treating mCRPC patients after prior therapy. Combining PARP inhibitors with androgen receptor pathway inhibitors has led to FDA-approved treatments for specific patient groups. Other combination strategies are being explored for improved outcomes in mCRPC.
|
|
|
|
|
|
|
|
|
|
|
| Serial Next-Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024
|
| Alan Bryce, MD
|
| Alan Bryce highlights the significance of serial next-generation sequencing in castrate-resistant prostate cancer and the role of PARP inhibitors. He emphasizes the importance of re-testing due to tumor evolution and test inaccuracies, illustrated by a case where a somatic BRCA2 mutation was detected after negative initial germline testing, guiding treatment with rucaparib.
|
|
|
|
|
|
| Real-World Treatment Patterns of Metastatic Prostate Cancer with Enhanced Access to Homologous Recombination Repair Genomic Testing and PARP Inhibitors |
| Steven M. Yip, MD, MSc |
| Steven Yip presents on real-world treatment patterns of metastatic prostate cancer with enhanced access to homologous recombination repair (HRR) genomic testing and PARP inhibitors. Around 25% of individuals with mCRPC possess HRR genomic alterations, impacting prognosis and treatment decisions. |
|
|
|
|
|
| LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) |
| Shahneen Sandhu, MBBS, FRACP |
| Shahneen Sandhu presented the findings of the LuPARP phase 1 trial, which evaluated the combination of 177Lu-PSMA-617 and olaparib in patients with metastatic castration-resistant prostate cancer. This combination aimed to intensify DNA damage and improve efficacy by promoting radiosensitization. |
|
|
|
|
|
| PARP Inhibitors: For Which Mutations and When? |
| Bertrand Tombal, MD, Ph.D. |
| Bertrand Tombal delivered a state-of-the-art lecture at the 2023 EAU congress, focusing on the timing and patient selection for PARP inhibitor use in metastatic castrate-resistant prostate cancer. He highlights the importance of genetic testing for DNA repair mutations, particularly in patients progressing on androgen receptor pathway inhibitors (ARPi), with olaparib recommended for those with BRCA1/2 mutations. |
|
|
|
|
|
|
